摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

[3-Chloro-2'-methyl-(1,1'-biphenyl)-4-yl]-(11-methyl-5,11-dihydro-benzo[b]pyrido [2,3-e][1,4]diazepin-6-yl)-methanone | 473717-68-9

中文名称
——
中文别名
——
英文名称
[3-Chloro-2'-methyl-(1,1'-biphenyl)-4-yl]-(11-methyl-5,11-dihydro-benzo[b]pyrido [2,3-e][1,4]diazepin-6-yl)-methanone
英文别名
[2-chloro-4-(2-methylphenyl)phenyl]-(11-methyl-5H-pyrido[3,2-c][1,5]benzodiazepin-6-yl)methanone
[3-Chloro-2'-methyl-(1,1'-biphenyl)-4-yl]-(11-methyl-5,11-dihydro-benzo[b]pyrido [2,3-e][1,4]diazepin-6-yl)-methanone化学式
CAS
473717-68-9
化学式
C27H22ClN3O
mdl
——
分子量
439.944
InChiKey
PQFVVVHBAAZSMY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6.1
  • 重原子数:
    32
  • 可旋转键数:
    2
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.11
  • 拓扑面积:
    36.4
  • 氢给体数:
    0
  • 氢受体数:
    3

文献信息

  • Biphenyl vasopressin agonists
    申请人:Wyeth
    公开号:US20030018024A1
    公开(公告)日:2003-01-23
    A compound of the formulae (I) or (II): 1 wherein: Y is a moiety selected from NR or —(CH 2 ) n ; wherein R is hydrogen or (C 1 -C 6 ) lower alkyl, and n is 1; 2 represents: (1) a phenyl ring optionally substituted with one or two substituents selected, independently, from the group comprising hydrogen, (C 1 -C 6 ) lower alkyl, halogen, cyano, CF 3 , hydroxy, (C 1 -C 6 ) lower alkoxy, (C 1 -C 6 ) lower alkoxy carbonyl, carboxy, —CONH 2 , —CONH[(C 1 -C 6 ) lower alkyl], —CON[(C 1 -C 6 ) lower alkyl] 2 ; or (2) a 6-membered aromatic (unsaturated) heterocyclic ring having one nitrogen atom, optionally substituted by (C 1 -C 6 ) lower alkyl, halogen or (C 1 -C 6 ) lower alkoxy; 3 represents: (1) a phenyl ring optionally substituted with one or two substituents selected, independently, from the group comprising hydrogen, (C 1 -C 6 ) lower alkyl, halogen, cyano, CF 3 , hydroxy, (C 1 -C 6 ) lower alkoxy, or (C 1 -C 6 ) lower alkoxy carbonyl, carboxy, —CONH 2 , —CONH[(C 1 -C 6 ) lower alkyl], —CON[(C 1 -C 6 ) lower alkyl] 2 ; or (2) a 5-membered aromatic (unsaturated) heterocyclic ring having one nitrogen atom, optionally substituted by (C 1 -C 6 ) lower alkyl, (C 1 -C 6 ) lower alkoxy, or halogen; or (3) a 6-membered aromatic (unsaturated) heterocyclic ring having one nitrogen atom, optionally substituted by (C 1 -C 6 ) lower alkyl, halogen, or (C 1 -C 6 ) lower alkoxy; 4 represents a 5-membered aromatic (unsaturated) heterocyclic ring having one sulfur atom, optionally substituted by (C 1 -C 6 ) lower alkyl, halogen, or (C 1 -C 6 ) lower alkoxy; R 1 is a moiety of the formula 5 and R 2 , R 3 , R 7 , R 8 and R 9 are, independently, selected from a group consisting of hydrogen, (C 1 -C 3 ) lower alkyl, OCH 3 , halogen, CF 3 , —SCH 3 , OCF 3 , SCF 3 , or CN; or a pharmaceutically acceptable salt, or pro-drug form thereof.
    化合物的分子式(I)或(II):其中:Y是从NR或—(CH2)n选择的基团;其中R是氢或(C1-C6)低碳烷基,n为1;2代表:(1)一个苯环,可选地取代一个或两个取代基,独立地选自包括氢,(C1-C6)低碳烷基,卤素,基,CF3,羟基,(C1-C6)低烷氧基,(C1-C6)低烷氧羰基,羧基,—CONH2,—CONH(C1-C6)低碳烷基,—CON(C1-C6)低碳烷基2的基团;或(2)含有一个氮原子的6成员芳香(不饱和)杂环环,可选地取代为(C1-C6)低碳烷基,卤素或(C1-C6)低烷氧基;3代表:(1)一个苯环,可选地取代一个或两个取代基,独立地选自包括氢,(C1-C6)低碳烷基,卤素,基, ,羟基,(C1-C6)低烷氧基,或(C1-C6)低烷氧羰基,羧基,—CONH2,—CONH(C1-C6)低碳烷基,—CON(C1-C6)低碳烷基2的基团;或(2)含有一个氮原子的5成员芳香(不饱和)杂环环,可选地取代为(C1-C6)低碳烷基,(C1-C6)低烷氧基,或卤素;或(3)含有一个氮原子的6成员芳香(不饱和)杂环环,可选地取代为(C1-C6)低碳烷基,卤素,或(C1-C6)低烷氧基;4代表含有一个原子的5成员芳香(不饱和)杂环环,可选地取代为(C1-C6)低碳烷基,卤素,或(C1-C6)低烷氧基;R1是公式5的基团,R2、R3、R7、R8和R9独立地选自氢,(C1-C3)低碳烷基,OCH3,卤素, ,—SCH3,O ,S ,或CN的基团;或其药学上可接受的盐或前药形式。
  • Biphenyl Vasopressin Agonists
    申请人:FAILLI Amedeo A.
    公开号:US20090227565A1
    公开(公告)日:2009-09-10
    A compound of the formulae (I) or (II): wherein: Y is a moiety selected from NR or —(CH 2 ) n ; wherein R is hydrogen or (C 1 -C 6 ) lower alkyl, and n is 1; represents: (1) a phenyl ring optionally substituted with one or two substituents selected, independently, from the group comprising hydrogen, (C 1 -C 6 ) lower alkyl, halogen, cyano, CF 3 , hydroxy, (C 1 -C 6 ) lower alkoxy, (C 1 -C 6 ) lower alkoxy carbonyl, carboxy, —CONH 2 , —CONH[(C 1 -C 6 ) lower alkyl], —CON[(C 1 -C 6 ) lower alkyl] 2 ; or (2) a 6-membered aromatic (unsaturated) heterocyclic ring having one nitrogen atom, optionally substituted by (C 1 -C 6 ) lower alkyl, halogen or (C 1 -C 6 ) lower alkoxy; represents: (1) a phenyl ring optionally substituted with one or two substituents selected, independently, from the group comprising hydrogen, (C 1 -C 6 ) lower alkyl, halogen, cyano, CF 3 , hydroxy, (C 1 -C 6 ) lower alkoxy, or (C 1 -C 6 ) lower alkoxy carbonyl, carboxy, —CONH 2 , —CONH[(C 1 -C 6 ) lower alkyl], —CON[(C 1 -C 6 ) lower alkyl] 2 ; or (2) a 5-membered aromatic (unsaturated) heterocyclic ring having one nitrogen atom, optionally substituted by (C 1 -C 6 ) lower alkyl, (C 1 -C 6 ) lower alkoxy, or halogen; or (3) a 6-membered aromatic (unsaturated) heterocyclic ring having one nitrogen atom, optionally substituted by (C 1 -C 6 ) lower alkyl, halogen, or (C 1 -C 6 ) lower alkoxy; represents a 5-membered aromatic (unsaturated) heterocyclic ring having one sulfur atom, optionally substituted by (C 1 -C 6 ) lower alkyl, halogen, or (C 1 -C 6 ) lower alkoxy; R 1 is a moiety of the formula and R 2 , R 3 , R 7 , R 8 and R 9 are, independently, selected from a group consisting of hydrogen, (C 1 -C 3 ) lower alkyl, OCH 3 , halogen, CF 3 , —SCH 3 , OCF 3 , SCF 3 , or CN; or a pharmaceutically acceptable salt, or pro-drug form thereof.
    化合物的结构式为(I)或(II),其中:Y是从NR或—(CH2)n选择的基团;其中R是氢或(C1-C6)低级烷基,n为1;表示:(1)苯环,可选地取代一个或两个取代基,独立地从羟基,(C1-C6)低级烷基,卤素,基,CF3,(C1-C6)低级烷氧基,(C1-C6)低级烷氧基羰基,羧基,—CONH2,—CONH[(C1-C6)低级烷基],—CON[(C1-C6)低级烷基]2中选择;或(2)具有一个氮原子的6元芳香(不饱和)杂环,可选地取代(C1-C6)低级烷基,卤素或(C1-C6)低级烷氧基;表示:(1)苯环,可选地取代一个或两个取代基,独立地从羟基,(C1-C6)低级烷基,卤素,基, ,(C1-C6)低级烷氧基,或(C1-C6)低级烷氧基羰基,羧基,—CONH2,—CONH[(C1-C6)低级烷基],—CON[(C1-C6)低级烷基]2中选择;或(2)具有一个氮原子的5元芳香(不饱和)杂环,可选地取代(C1-C6)低级烷基,(C1-C6)低级烷氧基或卤素;或(3)具有一个氮原子的6元芳香(不饱和)杂环,可选地取代(C1-C6)低级烷基,卤素或(C1-C6)低级烷氧基;表示具有一个原子的5元芳香(不饱和)杂环,可选地取代(C1-C6)低级烷基,卤素或(C1-C6)低级烷氧基;R1是公式的基团,R2、R3、R7、R8和R9独立地选择自氢,(C1-C3)低级烷基,OCH3,卤素, ,—SCH3,O ,S 或CN的群体;或其药学上可接受的盐或前药形式。
  • N-BIPHENYLCARBONYL- AND N-PHENYLPYRIDYLCARBONYL SUBSTITUTED BI- AND TRICYCLIC AZEPINES AND DIAZEPINES AS VASOPRESSING AGONISTS
    申请人:Wyeth
    公开号:EP1381370B1
    公开(公告)日:2007-03-07
  • US6903091B2
    申请人:——
    公开号:US6903091B2
    公开(公告)日:2005-06-07
  • US7223752B2
    申请人:——
    公开号:US7223752B2
    公开(公告)日:2007-05-29
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-(+)-2,2'',6,6''-四甲氧基-4,4''-双(二苯基膦基)-3,3''-联吡啶(1,5-环辛二烯)铑(I)四氟硼酸盐 (R)-N'-亚硝基尼古丁 (R)-DRF053二盐酸盐 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S,2'S)-(-)-[N,N'-双(2-吡啶基甲基]-2,2'-联吡咯烷双(乙腈)铁(II)六氟锑酸盐 (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 (1'R,2'S)-尼古丁1,1'-Di-N-氧化物 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸氯苯那敏-D6 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 韦德伊斯试剂 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非布索坦杂质66 非尼拉朵 非尼拉敏 雷索替丁 阿雷地平 阿瑞洛莫 阿扎那韦中间体 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 镉,二碘四(4-甲基吡啶)- 锌,二溴二[4-吡啶羧硫代酸(2-吡啶基亚甲基)酰肼]-